Table 1.
Baseline Characteristics of HCV+ patients who underwent treatment with all-oral DAA therapy stratified by HCC status.
| Characteristics | Entire cohort (n = 421) |
Non-HCC (n = 284) |
HCC (n = 137) |
p value* |
|---|---|---|---|---|
| Age, mean, years | 61, 8.3 | 60, 8.4 | 64, 7.4 | <0.0001 |
| Male, n (%) | 288 (68) | 185 (65) | 103 (75) | 0.04 |
| Race/Ethnicity, no. (%) | ||||
| Caucasian | 256 (65) | 165 (61) | 91 (67) | 0.81 |
| African American | 64 (16) | 45 (17) | 64 (14) | |
| Hispanic | 67 (16) | 47 (17) | 67 (15) | |
| Other | 22 (3) | 15 (5) | 22 (4) | |
| BMI (kg/m2), mean | 29, 5.3 | 29, 5.5 | 28, 4.9 | 0.21 |
| Former alcohol use, no. (%) | 100 (24) | 64 (23) | 36 (26) | 0.24 |
| Calculated MELD | 10, 4 | 11, 4.2 | 10, 3.6 | 0.15 |
| Child-Turcotte-Pugh Class, no. (%) | ||||
| A | 310 (74) | 201 (71) | 109 (81) | 0.03† |
| B | 107 (25) | 81 (29) | 26 (19) | |
| C | 3 (1) | 2 (0.1) | 1 (0.7) | |
| Ascites, no. (%) | 94 (22) | 75 (26) | 19 (14) | 0.004 |
| Hepatic encephalopathy, no. (%) | 69 (16) | 56 (20) | 13 (9) | 0.008 |
| AFP (ng/ml) | 31, 80.5 | 23, 45.6 | 50, 125.5 | 0.004 |
| Creatinine (mg/dl) | 1.09, 1.09 | 1.09, 1.28 | 1.07, 0.48 | 0.88 |
| Total bilirubin (mg/dl) | 1.46, 1.84 | 1.53, 1.62 | 1.33, 2.23 | 0.30 |
| Albumin (g/dl) | 3.65, 0.62 | 3.64, 0.63 | 3.68, 0.59 | 0.56 |
| INR | 1.18, 0.30 | 1.19, 0.30 | 1.15, 0.31 | 0.22 |
| AST (units/L) | 80, 59.6 | 80, 54.4 | 83, 69.3 | 0.60 |
| ALT (units/L) | 76, 69.5 | 73, 53.6 | 83, 94.1 | 0.17 |
| Platelets (µl) | 128, 80.2 | 126, 84.1 | 132, 71.6 | 0.47 |
| Sodium (mmol/L) | 137, 2.98 | 137, 2.94 | 138, 3.05 | 0.06 |
| HBsAg present, n (%) | 4 (1) | 3 (1) | 1 (0.7) | 0.76 |
| HBcIgG present, n (%) | 119 (30) | 68 (26) | 51 (39) | 0.02 |
| Log HCV viral load | 13.5, 5.8 | 13.5, 7.20 | 13.7, 6.14 | 0.79 |
| Treatment experienced, n (%) | 252 (60) | 173 (61) | 79 (58) | 0.52 |
| HCV genotype (%) | ||||
| 1 | 360 (86) | 244 (86) | 116 (85) | 0.16 |
| 2 | 22 (5) | 18 (6) | 4 (3) | |
| 3 | 35 (8) | 19 (7) | 16 (12) | |
| Other | 4 (0.01) | 3 (1) | 1 (0.07) | |
| Treatment classification**(%) | ||||
| Inadequate | 266 (63) | 187 (66) | 79 (58) | 0.12 |
| Adequate | 155 (37) | 97 (34) | 58 (42) |
Data are presented as mean, standard deviation or number (%).
HCV, hepatitis C virus; HCC, hepatocellular carcinoma; HCV-HCC, individuals with both hepatitis C and hepatocellular carcinoma; n, number; BMI, body mass index; MELD, model for end-stage liver disease; AFP, alpha fetoprotein; INR, international normalized ratio; AST, aspartate transaminase; ALT, alanine transaminase; HBsAg, hepatitis B surface antigen; HBcIgG, hepatitis B core IgG.
t test for continuous variables and Chi square or Fisher exact test for categorical variables for the comparison between non-HCC and HCC groups.
Treatment classified as inadequate or adequate based on current HCV treatment standards. Inadequate treatment was defined as simeprevir/sofosbuvir 12 weeks orsofosbuvir/ledipasivir 12 weeks in treatment experienced patients or sofosbuvir/ribavirin regimens.
Comparisons between Child-Turcotte-Pugh A vs. B or C.